$INNV Innovus Pharmaceuticals, Inc. ("Innovus Pha
Post# of 405
(Total Views: 552)
Posted On: 02/21/2019 6:52:12 AM
$INNV
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the submission of regulatory filings by its international distribution partner, Lavasta Pharma FZ-LLC, a company based in Dubai (“Lavasta”) for the commercialization of ProstaGorx® in the United Arab Emirates and Kuwait. Lavasta also has rights to this product in the Kingdom of Saudi Arabia, Algeria, Egypt, Lebanon, Jordan, Morocco, Tunisia, Bahrain, Oman, Qatar and Turkey, among other countries and is currently expected to continue to file for approval in the rest of its territory during this year.
Innovus signed an exclusive distribution agreement with Lavasta for ProstaGorx® in 2018 and already received an upfront payment for the license.
“We continue to expand the potential sales territories of our products. ProstaGorx® is our third product after Zestra® and Zestra Glide® expected to enter the Middle Eastern and North African countries,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Lavasta has committed a first order of 10,000 units upon approval of the product,” continued Dr. Damaj.
About ProstaGorx® and Prostate Health
Prostate health issues affect millions of men and it is important to offer a natural, clinically tested, alternative product with a potentially approved claim for urologic symptoms of Benign Prostatic Hyperplasia (“BPH”). With multiple published clinical trials, ProstaGorx® ingredients have been shown to:
Work with the prescription drug finasteride to reduce actual prostate weight;
Regulate dihydrotestosterone (“DHT”) production and hormones that influence prostate volume;
Clinically reduce nocturia, and improve prostate symptoms in men with BPH or prostatitis;
Clinically reduce overall rate of progression of prostate cancer in men; and
Decrease serum prostate-specific antigen (“PSA”) levels, suppression of tumor growth and support urinary function.
An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 40–50% of these men, BPH becomes clinically significant. BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States.
ProstaGorx® is approved by Health Canada as Natural Health Product for the symptoms of Benign Prostatic Hyperplasia (BPH) and has been commercially available in Canada since 2018.
Innovus Pharmaceuticals, Inc. ("Innovus Pharma" or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today the submission of regulatory filings by its international distribution partner, Lavasta Pharma FZ-LLC, a company based in Dubai (“Lavasta”) for the commercialization of ProstaGorx® in the United Arab Emirates and Kuwait. Lavasta also has rights to this product in the Kingdom of Saudi Arabia, Algeria, Egypt, Lebanon, Jordan, Morocco, Tunisia, Bahrain, Oman, Qatar and Turkey, among other countries and is currently expected to continue to file for approval in the rest of its territory during this year.
Innovus signed an exclusive distribution agreement with Lavasta for ProstaGorx® in 2018 and already received an upfront payment for the license.
“We continue to expand the potential sales territories of our products. ProstaGorx® is our third product after Zestra® and Zestra Glide® expected to enter the Middle Eastern and North African countries,” said Innovus Pharma CEO, Dr. Bassam Damaj. “Lavasta has committed a first order of 10,000 units upon approval of the product,” continued Dr. Damaj.
About ProstaGorx® and Prostate Health
Prostate health issues affect millions of men and it is important to offer a natural, clinically tested, alternative product with a potentially approved claim for urologic symptoms of Benign Prostatic Hyperplasia (“BPH”). With multiple published clinical trials, ProstaGorx® ingredients have been shown to:
Work with the prescription drug finasteride to reduce actual prostate weight;
Regulate dihydrotestosterone (“DHT”) production and hormones that influence prostate volume;
Clinically reduce nocturia, and improve prostate symptoms in men with BPH or prostatitis;
Clinically reduce overall rate of progression of prostate cancer in men; and
Decrease serum prostate-specific antigen (“PSA”) levels, suppression of tumor growth and support urinary function.
An estimated 50% of men have histologic evidence of BPH by age 50 and 75% by age 80; in 40–50% of these men, BPH becomes clinically significant. BPH was one of the ten most common, and costly, diseases in men older than 50 years of age in a recent study in the United States.
ProstaGorx® is approved by Health Canada as Natural Health Product for the symptoms of Benign Prostatic Hyperplasia (BPH) and has been commercially available in Canada since 2018.
(0)
(0)